ONC 212
Alternative Names: ONC-212Latest Information Update: 20 Jun 2025
At a glance
- Originator Oncoceutics
- Developer Chimerix; Oncoceutics
- Class 3-ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Imidazoles; Pyrimidines; Small molecules
- Mechanism of Action Apoptosis stimulants; Endopeptidase Clp stimulants; G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adenocarcinoma; Biliary cancer; Ewing's sarcoma; Glioma; Liver cancer; Pancreatic cancer
- No development reported Acute myeloid leukaemia
Most Recent Events
- 20 Jun 2025 Pharmacodynamics data from preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 21 Apr 2025 Chimerix has been acquired by Jazz Pharmaceuticals plc
- 05 Apr 2024 Preclinical trials in Biliary cancer in USA (unspecified route) prior to April 2024